Thomsen, WJ; Grottick, AJ; Menzaghi, F; Reyes-Saldana, H; Espitia, S; Yuskin, D; Whelan, K; Martin, M; Morgan, M; Chen, W; Al-Shamma, H; Smith, B; Chalmers, D; Behan, D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J. Pharmacol. Exp. Ther., 1 May 2008, 325 (2), 577–587. 491 kB. https://doi.org/10.1124/jpet.107.133348
Smith, BM; Smith, JM; Tsai, JH; Schultz, JA; Gilson, CA; Estrada, SA; Chen, RR; Park, DM; Prieto, EB; Gallardo, CS; Sengupta, D; Thomsen, WJ; Saldana, HR; Whelan, KT; Menzaghi, F; Webb, RR; Beeley, NRA. Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity Bioorg. Med. Chem. Lett., 1 Mar 2005, 15 (5), 1467–1470. 122 kB. https://doi.org/10.1016/j.bmcl.2004.12.080 #15
Smith, BM; Smith, JM; Tsai, JH; Schultz, JA; Gilson, CA; Estrada, SA; Thomsen, WJ. Discovery and Structure−Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT2C Receptor Agonist for the Treatment of Obesity J. Med. Chem., 1 Jan 2008, 51 (2), 305–313. 158 kB. https://doi.org/10.1021/jm0709034 #7d MS,NMR
Pawar, RS; Grundel, E. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs) Drug Test. Anal., 1 Mar 2017, 9 (3), 500-517. 601 kB. https://doi.org/10.1002/dta.1980
Helm, K. Synthese und funktionelle In-vitro-Pharmakologie neuer Liganden des 5-HT2A-Rezeptors aus der Klasse Ph. D. Thesis, Universität Regensburg, Dresden, 1 Jan 2014. 3.2 MB. #15 LC,MS,NMR,IR
Cheng, J; Kozikowski, AP. We need 2C but not 2B: Developing serotonin 2C (5-HT2C) receptor agonists for the treatment of CNS disorders ChemMedChem, 1 Dec 2015, 10 (12), 1963–1967. 1.1 MB. https://doi.org/10.1002/cmdc.201500437 #6
Cheng, J; McCorvy, JD; Giguere, PM; Zhu, H; Kenakin, T; Roth, BL; Kozikowski, AP. Design and discovery of functionally selective serotonin 2C (5-HT2C) receptor agonists J. Med. Chem., 10 Nov 2016, 59 (21), 9866–9880. 4.8 MB. https://doi.org/10.1021/acs.jmedchem.6b01194 MS,NMR
Zhang, G; Cheng, J; McCorvy, JD; Lorello, PJ; Caldarone, BJ; Roth, BL; Kozikowski, AP. Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications J. Med. Chem., 27 Jul 2017, 60 (14), 6273–6288. 3.5 MB. https://doi.org/10.1021/acs.jmedchem.7b00584 #2 MS,NMR
Cheng, J; Giguère, PM; Onajole, OK; Lv, W; Gaisin, A; Gunosewoyo, H; Schmerberg, CM; Pogorelov, VM; Rodriguiz, RM; Vistoli, G; Wetsel, WC; Roth, BL; Kozikowski, AP. Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents J. Med. Chem., 26 Feb 2015, 58 (4), 1992–2002. 1.9 MB. https://doi.org/10.1021/jm5019274 #1 MS,NMR
Oh, S; Kim, KS; Chung, YS; Shong, M; Park, SB. Anti-obesity agents: A focused review on the structural classification of therapeutic entities Curr. Top. Med. Chem., 1 Apr 2009, 9 (6), 466–481. 438 kB. https://doi.org/10.2174/156802609788897862
Cheng, J; Giguere, PM; Schmerberg, CM; Pogorelov, VM; Rodriguiz, RM; Huang, X; Zhu, H; McCorvy, JD; Wetsel, WC; Roth, BL; Kozikowski, AP. Further advances in optimizing (2-phenylcyclopropyl)methylamines as novel serotonin 2C agonists: Effects on hyperlocomotion, prepulse inhibition, and cognition models J. Med. Chem., 28 Jan 2016, 59 (2), 578–591. 2.9 MB. https://doi.org/10.1021/acs.jmedchem.5b01153 #1 MS,NMR